# Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

Study · id `cardio:ct-nct04263038` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04263038](<https://clinicaltrials.gov/study/NCT04263038>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04263038

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

## Technical summary

Registry record NCT04263038. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-15 (actual); primary completion 2028-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 276 participants (planned count; ClinicalTrials.gov record NCT04263038, source copy `cardio:ctgov-nct04263038-2026-05-22`, retrieved 2026-10-31)
- Started: 2020-05-15 (actual) (ClinicalTrials.gov record NCT04263038, source copy `cardio:ctgov-nct04263038-2026-05-22`, retrieved 2026-10-31)
- Primary completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT04263038, source copy `cardio:ctgov-nct04263038-2026-05-22`, retrieved 2026-10-31)
- Completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT04263038, source copy `cardio:ctgov-nct04263038-2026-05-22`, retrieved 2026-10-31)
- Countries: Belgium; Canada; France; Netherlands; Switzerland (ClinicalTrials.gov record NCT04263038, source copy `cardio:ctgov-nct04263038-2026-05-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04263038-2026-05-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
- Acronym: SAFE-SSPE
- Condition: Pulmonary Embolism
- Condition: Embolism
- Condition: Embolism and Thrombosis
- Condition: Lung Diseases
- Condition: Cardiovascular Diseases
- Condition: Respiratory Tract Diseases
- Condition: Venous Thromboembolism
- Condition: Anticoagulant-induced Bleeding
- Condition: Bleeding
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Placebo
- Lead sponsor: Drahomir Aujesky
- Lead sponsor class: OTHER
- Collaborator: University of Bern
- Collaborator class: OTHER
- Collaborator: Schweizerischer Nationalfonds
- Collaborator class: OTHER
- Collaborator: Leiden University Medical Center
- Collaborator class: OTHER
- Collaborator: The Ottawa Hospital
- Collaborator class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as a collaborator: University of Bern (`cardio:org-university-of-bern`)
- Registry lists this organization as a collaborator: Leiden University Medical Center (`cardio:org-leiden-university-medical-center`)
- Registry lists this organization as a collaborator: The Ottawa Hospital (`cardio:org-the-ottawa-hospital`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: b00baca0ee19635cd6bac35c136a504f9cf352e1393d371826522105ab9a8846
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
